Evidence map›Paper›PMID 29948762›Full record

ArticleMaternal and child health journal2018

Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States.

Rebecca A Malouin, Laurel Mckernan, Ann Forsberg, Dunlei Cheng, John Drake, Kathryn McLaughlin, Marisela Trujillo

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Maternal and child health journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. The Bleeding Disorders Research Collaborative.Blood vessels, thrombosis & hemostasis · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Rebecca A MalouinDepartment of Family and Community Medicine, Michigan State University, 909 Fee Road, Room B201, East Lansing, MI, 49923, USA. Rebecca.Malouin@hc.msu.edu.
Laurel MckernanComprehensive Hemophilia and Thrombosis Center, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH, 03756, USA.
Ann ForsbergNational Hemophilia Program Coordinating Center, American Thrombosis and Hemostasis Network, 72 Treasure Lane, Riverwoods, ILL, 00615, USA.
Dunlei ChengAmerican Thrombosis and Hemostasis Network, 72 Treasure Lane, Riverwoods, ILL, 00615, USA.
John DrakeGreat Plains Regional Hemophilia Network, Gulf States Hemophilia and Thrombophilia Center, University of Texas Health Science Center at Houston, 6655 Travis, Suite 400, Houston, TX, USA.
Kathryn McLaughlinGenetic Services Branch, Maternal and Child Health Bureau, Health Resources and Services Administration, Parklawn Building, Room 18A-19, 5600 Fishers Lane, Rockville, MD, 20857, USA.
Marisela TrujilloGulf States Hemophilia and Thrombophilia Center, University of Texas Health Science Center Houston, 6655 Travis St., Suite 400, Houston, TX, 77030, USA.
American Thrombosis and Hemostasis Network · USDartmouth–Hitchcock Medical Center · USHealth Resources and Services Administration · USMichigan State University · USThe University of Texas Health Science Center at Houston · US

Funding

Maternal and Child Health Bureau UC8MC24027
6 · The paper itself

Abstract

Purpose Hemophilia Treatment Centers (HTCs) provide integrated and comprehensive services to individuals affected with rare bleeding disorders, such as hemophilia and Von Willebrand disease. Through the 340 Drug Pricing Program, HTCs may use pharmacy income to support clinical staff and patient services. The objective of this study was to describe the impact of the 340B program funding on services and support provided by HTCs to persons affected by rare bleeding disorders. Description Federally designated comprehensive HTCs with established 340B programs were invited to participate in a mailed survey in 2014. Participants were requested to report on 340B program-funded staff and services in the calendar year 2013. Assessment The 31 of 37 HTCs responding served over 10,000 individuals, or one-third of the national HTC patient population. The majority of responding HTCs reported that 340B program income supported over 90% of staff such as nurses, social workers, and physical therapists. Conclusion The results from this survey of 31 centers with established programs demonstrates the HTCs' reliance on 340B program support for vital comprehensive services, that are otherwise non-reimbursable, and highlights the importance of the 340B program in sustaining the high quality of care and in increasing access for a geographically dispersed, medically vulnerable population.

Indexed as

Comprehensive Health CareDrug CostsFemaleHemophilia AHumansInsurance, Pharmaceutical ServicesMalePatient CarePharmaceutical ServicesPrescription DrugsSafety-net ProvidersSurveys and QuestionnairesUnited StatesPrescription Drugs340B Drug Pricing ProgramChildren with special healthcare needsComprehensive care modelHemophiliaHemophilia treatment centers

Identifiers

PMID29948762
PMCPMC6096501
OpenAlexW2807979428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.